These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 23461897)
1. Butyrate-producing bacteria as pharmabiotics for inflammatory bowel disease. Marteau P Gut; 2013 Dec; 62(12):1673. PubMed ID: 23461897 [No Abstract] [Full Text] [Related]
2. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics. Eeckhaut V; Ducatelle R; Sas B; Vermeire S; Van Immerseel F Gut; 2014 Feb; 63(2):367. PubMed ID: 23766442 [No Abstract] [Full Text] [Related]
3. Butyricicoccus pullicaecorum in inflammatory bowel disease. Eeckhaut V; Machiels K; Perrier C; Romero C; Maes S; Flahou B; Steppe M; Haesebrouck F; Sas B; Ducatelle R; Vermeire S; Van Immerseel F Gut; 2013 Dec; 62(12):1745-52. PubMed ID: 23263527 [TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of the upper gastrointestinal passage of a novel butyrate producing isolate to counterbalance dysbiosis in inflammatory bowel disease. Geirnaert A; Debruyne B; Eeckhaut V; Van Immerseel F; Boon N; Van de Wiele T Commun Agric Appl Biol Sci; 2012; 77(1):195-9. PubMed ID: 22558780 [No Abstract] [Full Text] [Related]
5. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Fedorak R; Demeria D Gastroenterol Clin North Am; 2012 Dec; 41(4):821-42. PubMed ID: 23101689 [TBL] [Abstract][Full Text] [Related]
8. Transmissible agents in inflammatory bowel disease: 1980. Beeken WL Med Clin North Am; 1980 Nov; 64(6):1021-35. PubMed ID: 7007757 [No Abstract] [Full Text] [Related]
9. Executive summary of the AGA-NFIC sponsored workshop on infectious agents in inflammatory bowel disease. Thayer WR Dig Dis Sci; 1979 Oct; 24(10):781-4. PubMed ID: 487915 [No Abstract] [Full Text] [Related]
10. Clinical utility of probiotics in inflammatory bowel disease. Cain AM; Karpa KD Altern Ther Health Med; 2011; 17(1):72-9. PubMed ID: 21614946 [TBL] [Abstract][Full Text] [Related]
11. Probiotics and IBD. De Greef E; Vandenplas Y; Hauser B; Devreker T; Veereman-Wauters G Acta Gastroenterol Belg; 2013 Mar; 76(1):15-9. PubMed ID: 23650777 [TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of the upper gastrointestinal passage of a novel butyrate producing isolate to counterbalance dysbiosis in inflammatory bowel disease. Geirnaert A; Debruyne B; Eeckhaut V; Van Immerseel F; Booni N; Van de Wiele T Commun Agric Appl Biol Sci; 2012; 77(1):45-9. PubMed ID: 22558754 [No Abstract] [Full Text] [Related]
13. [Crohn disease, ulcerative colitis. When bacteria attack the intestinal wall....]. Duchmann R; Lochs H; Kruis W MMW Fortschr Med; 1999 Dec; 141(51-52):48-51. PubMed ID: 10949626 [TBL] [Abstract][Full Text] [Related]
14. Qualitative and Quantitative Characteristics of Selected Bacterial Groups in Children with Inflammatory Bowel Diseases. Roszak D; Gałęcka MS; Cichy W; Szachta P Pol J Microbiol; 2016; 65(2):219-24. PubMed ID: 28520330 [TBL] [Abstract][Full Text] [Related]
15. Impact of probiotics on colonic microflora in patients with colitis: a prospective double blind randomised crossover study. Ahmed J; Reddy BS; Mølbak L; Leser TD; MacFie J Int J Surg; 2013; 11(10):1131-6. PubMed ID: 24060951 [TBL] [Abstract][Full Text] [Related]
17. Human microbiota and inflammatory bowel diseases: new pieces of an intricate puzzle. Pellicano R Minerva Gastroenterol Dietol; 2019 Sep; 65(3):171-172. PubMed ID: 31602969 [No Abstract] [Full Text] [Related]